To validate the effect of MYCMI-7 on endogenous MYC:MAX interactions, isPLA (8, 30) was used in MCF7, a breast cancer cell line we have used extensively to validate the effect of MYC:MAX inhibitors on endogenous MYC:MAX interactions (8). The gene discussed is MAX; the disease is breast carcinoma.